(Sharecast News) - Hikma Pharmatheuticals: Citigroup downgrades to neutral with a target price of 1,980p.
Jupiter Fund Management: Berenberg reiterates hold with a target price of 367p.
Centamin: Berenberg reiterates hold with a target price of 127p.
Hummingbird Resources: Berenberg reiterates buy with a target price of 38p.
MJ Gleeson: Canaccord reiterates hold with a target price of 960p.
Imperial Brands: Deutsche Bank reiterates buy with a target price of 2,400p.
National Grid: Barclays reiterates overweight with a target price of 1,115p.
Segro: Deutsche Bank downgrades to hold with a target price of 810p.
AstraZeneca: UBS reiterates sell with a target price of 5,800p.
Just Eat: Barclays reiterates overweight with a target price 8,500p.
Reckitt Benckiser Group: JP Morgan reiterates overweight with a target price of 8,500p.
Royal Bank of Scotland: JP Morgan reiterates overweight with a target price of 260p.
Ashtead: JP Morgan reiterates overweight with a target price of 3,250p.
Dunelm: RBC reiterates sector performer with a target price of 1,250p.
RELX: UBS reiterates sell with a target price of 1,825p.
Barclays: UBS reiterates buy with a target price of 205p.
Associated British Foods: UBS reiterates buy with a target price of 3,200p.
Meggitt: Citigroup downgrades to neutral with a target price of 730p.
Astrazeneca (AZN)
Barclays (BARC)
Jupiter Fund Management (JUP)
National Grid (NG.)
Relx (REL)
Hikma Pharmaceuticals (HIK)
Centamin PLC (CEY)
Dunelm (DNLM)
Segro (SGRO)
AB Foods (ABF)
MJGleeson (GLE)
Imperial Brands (IMB)
Ashtead Group (AHT)Today 10:04
AstraZeneca notes positive trial results for Calquence treatment
(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for pr...
